Hengrui is a leading innovation-driven pharmaceutical company in China, founded in 1970 and headquartered in Lianyungang, Jiangsu. The company focuses on the research, development, manufacturing and commercialization of high-quality medicines, with key therapeutic areas including oncology, metabolic and cardiovascular diseases, immunological and respiratory diseases, and neuroscience. Hengrui has established a broad innovative drug pipeline and is pursuing a globalisation strategy through overseas clinical development, regulatory approvals and partnerships with international pharmaceutical companies. In 2025, Hengrui generated RMB 31.63 billion in revenue and invested RMB 8.72 billion in R&D, equivalent to 27.58% of revenue. The company was listed on the Shanghai Stock Exchange in 2000 and completed its Hong Kong listing in 2025, becoming an A+H dual-listed pharmaceutical company.

恒瑞医药成立于1970年，总部位于江苏连云港，是中国领先的创新驱动型制药企业之一，主要从事高质量药品的研发、生产与商业化，重点布局肿瘤、代谢及心血管疾病、免疫与呼吸系统疾病以及神经科学等治疗领域。公司已建立较为丰富的创新药研发管线，并通过海外临床开发、国际注册及与跨国药企合作等方式持续推进全球化发展。2025年，恒瑞医药实现营业收入316.3亿元，研发投入87.2亿元，占营业收入的27.58%；创新药销售收入163.4亿元。公司于2000年在上海证券交易所上市，并于2025年在香港联交所主板上市，成为“A+H”双重上市药企。